249 related articles for article (PubMed ID: 15885233)
1. A case control study of glycoprotein status in ovarian carcinoma.
Aranganathan S; Senthil K; Nalini N
Clin Biochem; 2005 Jun; 38(6):535-9. PubMed ID: 15885233
[TBL] [Abstract][Full Text] [Related]
2. Serum sialic acid, fucose, sialic acid/fucose ratio as tumor markers in oral cancer.
Ghosh M; Nayak BR
Ann Dent; 1991; 50(2):33-5, 48. PubMed ID: 1785913
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of glycoproteins as prognosticators in head and neck malignancy.
Bathi RJ; Nandimath K; Kannan N; Shetty P
Indian J Dent Res; 2001; 12(2):93-9. PubMed ID: 11665403
[TBL] [Abstract][Full Text] [Related]
4. Plasma lipid-associated sialic acid and serum CA 125 as indicators of disease status with advanced ovarian cancer.
Vardi JR; Tadros GH; Foemmel R; Shebes M
Obstet Gynecol; 1989 Sep; 74(3 Pt 1):379-83. PubMed ID: 2761915
[TBL] [Abstract][Full Text] [Related]
5. Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases.
Shen Z; Wu M; Elson P; Kennedy AW; Belinson J; Casey G; Xu Y
Gynecol Oncol; 2001 Oct; 83(1):25-30. PubMed ID: 11585410
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of serum sialic acid, heat stable alkaline phosphatase and fucose as markers of breast carcinoma.
Patel PS; Baxi BR; Adhvaryu SG; Balar DB
Anticancer Res; 1990; 10(4):1071-4. PubMed ID: 2382978
[TBL] [Abstract][Full Text] [Related]
7. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of total and lipid bound sialic acid levels in oral pre-cancerous conditions and oral cancer.
Rajpura KB; Patel PS; Chawda JG; Shah RM
J Oral Pathol Med; 2005 May; 34(5):263-7. PubMed ID: 15817068
[TBL] [Abstract][Full Text] [Related]
9. Tumor markers in epithelial ovarian cancer. Clinical applications.
Hempling RE
Obstet Gynecol Clin North Am; 1994 Mar; 21(1):41-61. PubMed ID: 8015766
[TBL] [Abstract][Full Text] [Related]
10. Biochemical markers in ovarian cancer.
Kiricuta I; Bojan O; Munteanu S
Arch Geschwulstforsch; 1986; 56(1):35-8. PubMed ID: 3964031
[TBL] [Abstract][Full Text] [Related]
11. Acute phase reactants and circulating immune complexes in patients with ovarian carcinoma.
Dobryszycka W; Gerber J; Zuwała-Jagiełło J; Ujec M
Arch Immunol Ther Exp (Warsz); 1991; 39(1-2):41-50. PubMed ID: 1725104
[TBL] [Abstract][Full Text] [Related]
12. Clinical application of serum levels of sialic acid, fucose and seromucoid fraction as tumour markers in human leukemias.
Patel PS; Adhvaryu SG; Balar DB; Parikh BJ; Shah PM
Anticancer Res; 1994; 14(2B):747-51. PubMed ID: 8010734
[TBL] [Abstract][Full Text] [Related]
13. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
[TBL] [Abstract][Full Text] [Related]
14. Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer.
Camlica H; Duranyildiz D; Tas F; Yasasever V
Am J Clin Oncol; 2008 Dec; 31(6):585-8. PubMed ID: 19060592
[TBL] [Abstract][Full Text] [Related]
15. Importance of glycoproteins in human cancer.
Patel PS; Raval GN; Rawal RM; Patel MM; Balar DB; Patel DD
Indian J Biochem Biophys; 1997; 34(1-2):226-33. PubMed ID: 9343956
[TBL] [Abstract][Full Text] [Related]
16. Proteomic studies of early-stage and advanced ovarian cancer patients.
Wang J; Zhang X; Ge X; Guo H; Xiong G; Zhu Y
Gynecol Oncol; 2008 Oct; 111(1):111-9. PubMed ID: 18703221
[TBL] [Abstract][Full Text] [Related]
17. [The diagnostic value of the assay of lactate dehydrogenese combined with other tumor markers in ovarian cancer].
Tang BJ; Li L; Xu J
Zhonghua Fu Chan Ke Za Zhi; 1994 Jun; 29(6):336-9, 381. PubMed ID: 8001406
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.
Havrilesky LJ; Whitehead CM; Rubatt JM; Cheek RL; Groelke J; He Q; Malinowski DP; Fischer TJ; Berchuck A
Gynecol Oncol; 2008 Sep; 110(3):374-82. PubMed ID: 18584856
[TBL] [Abstract][Full Text] [Related]
19. Identification and confirmation of differentially expressed fucosylated glycoproteins in the serum of ovarian cancer patients using a lectin array and LC-MS/MS.
Wu J; Xie X; Liu Y; He J; Benitez R; Buckanovich RJ; Lubman DM
J Proteome Res; 2012 Sep; 11(9):4541-52. PubMed ID: 22827608
[TBL] [Abstract][Full Text] [Related]
20. [Tumor markers in the monitoring of ovarian cancer].
Xu SX
Zhonghua Fu Chan Ke Za Zhi; 1990 Nov; 25(6):345-7, 383. PubMed ID: 2282861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
